2.1
Pembrolizumab (Keytruda, MSD), in combination with carboplatin and paclitaxel, is indicated for 'the first-line treatment of primary advanced or recurrent endometrial carcinoma in adults'.
2 Information about pembrolizumab
Marketing authorisation indication
Dosage in the marketing authorisation
2.2
The dosage schedule is available in the summary of product characteristics for pembrolizumab.
Price
2.3
The list price is £2,630.00 for a 25 mg per 1 ml concentrate for solution for infusion 4‑ml vial (excluding VAT; BNF online accessed July 2025).
2.4
The company has a commercial arrangement. This makes pembrolizumab available to the NHS with a discount. The size of the discount is commercial in confidence.
Carbon Reduction Plan
2.5
For information, the Carbon Reduction Plan for UK carbon emissions is published on MSD's webpage on responsibility.